We are thrilled to reintroduce Across the Consortium, a monthly article showcasing the latest news and events from our member institutions. In this edition, we proudly add our newest member, Fred Hutchinson Cancer Center, which serves as the cancer program for UW Medicine—the University of Washington’s health system—joining our consortium of now 16 institutions.
February 11, 2025: The Big Ten Cancer Research Consortium (Big Ten CRC), a collaboration of the cancer centers of Big Ten Conference universities united to transform cancer research by leveraging their scientific and clinical expertise, welcomed new member Fred Hutch Cancer Center, an independent, nonprofit organization that serves as the cancer program for UW Medicine (the University of Washington’s health system). It is the first new institution to join the consortium following the recent expansion of the Big Ten Conference. Read More
December 17, 2024: A Big Ten Cancer Research Consortium trial, BTCRC-LYM20-463, titled, "A Phase I/II Study of Tazemetostat Combined with Abbreviated Rituximab/Bendamustine Therapy for High Tumor Burden Follicular Lymphoma in Frontline Treatment: A Big Ten Cancer Research Consortium Study," was presented as a poster presentation at the 2024 American Society of Hematology Annual Meeting on December 9, 2024. Congratulations to Vaishalee P Kenkre, MD, of the University of Wisconsin School of Medicine and Public Health, Andrew M Evens, DO, MBA, MSc, of Rutgers Cancer Institute and all co-authors! Read More
December 6, 2024: A Big Ten Cancer Research Consortium (Big Ten CRC) trial titled, “A Phase II Study of Pembrolizumab Plus Fulvestrant in Hormone Receptor Positive, HER-2 Negative Advanced/Metastatic Breast Cancer Patients: Big Ten Cancer Research Consortium BTCRC-BRE16-042” has been accepted as a poster presentation (P2-07-21) at the 2024 San Antonio Breast Cancer Symposium on December 11, 2024 from 5:30 pm – 7:30 pm. Congratulations to all co-authors and study teams involved in the study! Read More
December 4, 2024: A Big Ten Cancer Research Consortium trial titled, “Alpelisib (BYL719) with continued endocrine therapy following progression on endocrine therapy in hormone receptor–positive, HER2-negative, PIK3CA-mutant metastatic breast cancer: A Big Ten Cancer Research Consortium Study (BTCRC-BRE19-409)” has been accepted for a poster presentation at the 2024 San Antonio Breast Cancer Symposium on December 11, 2024 from 5:30 pm – 7:00 pm. Congratulations to all co-authors and study teams involved in the study! Read More
December 2, 2024: A Big Ten Cancer Research Consortium (Big Ten CRC) study, BTCRC-LUN16-081, led by Greg Durm, MD, of IU Simon Comprehensive Cancer Center, was published in the Journal of Thoracic Oncology in October 2024. The article is titled, “Analysis of Circulating Tumor DNA Predicts Outcomes of Short-Course Consolidation Immunotherapy in Unresectable Stage III NSCLC.” Congratulations to all co-authors and study teams whose hard work led to this publication. Read More
October 1, 2024: The Big Ten Cancer Research Consortium (Big Ten CRC) congratulates Kari Wisinski, MD, on receiving the 2024 Pat Loehrer Award for Exemplary Collaboration in Cancer Research. Read More
October 10, 2024: A Big Ten Cancer Research Consortium (Big Ten CRC) study, BTCRC-GI15-015, led by Al B. Benson III, MD, of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, was published in The Oncologist on September 18, 2024. The article is titled, “A phase II study of FOLFOX combined with nab-paclitaxel in the treatment of metastatic or advanced unresectable gastric, gastroesophageal junction adenocarcinoma: a Big Ten Cancer Research Consortium trial.” Congratulations to all co-authors and study teams whose hard work led to this publication. Read More
Subscribe to the Big Ten CRC Newsletter
X
Facebook
YouTube